Comparison of Dexamethasone Implant and Anti-VEGF Agents in the Treatment of Naive Diabetic Macular Oedema: A Prospective Cohort Study

Introduction: Diabetic Retinopathy (DR) is one of the common microvascular complications of diabetes. In patients with DR, the most frequent cause of vision loss is Diabetic Macular oedema (DME). In the present era, anti-Vascular Endothelial Growth Factor (anti-VEGF) agents are the mainstay of t...

Full description

Bibliographic Details
Published in:	Journal of Clinical and Diagnostic Research
Main Authors:	Vanaja Iyer, Gayatree Mohanty, CS Lalitha, Manmath Kumar Das, Mehak Sethi
Format:	Article
Language:	English
Published:	JCDR Research and Publications Private Limited 2023-11-01
Subjects:	diabetic retinopathy microvascular complications ranibizumab vascular endothelial growth factor
Online Access:	https://www.jcdr.net/articles/PDF/18739/65352_CE[Ra1]_F(IS)_QC(KK_RDW_IS)_PF1(AKA_KM)_PFA(AKA_KM)_PN(KM).pdf

Similar Items

Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy
by: Serhad Nalçacı, et al.
Published: (2019-04-01)

Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema
by: Santosh K Mahapatra, et al.
Published: (2024-01-01)

Effect of Ranibizumab in Patients with Treatment-Naïve Retinopathy of Prematurity
by: Hina Khalid, et al.
Published: (2025-08-01)

Histopathological study of the effect of sunitinib in treatment of retinal angiogenesis induced by VEGF 165 in rabbits’eyes
by: Shahad Salah Aldeen, et al.
Published: (2018-12-01)

Comparison of the efficacy of intravitreal Anti-VEGF versus intravitreal dexamethasone implant in treatment resistant diabetic Macular Edema
by: Hakan Koc, et al.
Published: (2023-03-01)

A New Anti-VEGF Inhibitor, Aflibercept: Treatment Outcomes Of Neovascular Macular Degeneration Refractory To Other Anti-VEGF Agents
by: Kiran Turaka
Published: (2014-04-01)

Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients
by: J. M. Ruiz-Moreno, et al.
Published: (2020-09-01)

Assessment of Anti-VEGFs in Treating Diabetic Macular Edema in Alfaisal Eye Center, Khartoum, Sudan, 2019
by: Ahmedalgabri RHM, et al.
Published: (2022-04-01)

A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy
by: Robert Hodgson, et al.
Published: (2025-01-01)

Review of effects of anti-VEGF treatment on refractive error
by: Mintz-Hittner HA, et al.
Published: (2016-06-01)

Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity
by: Parijat Chandra, et al.
Published: (2019-01-01)

Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study
by: Yule Xu, et al.
Published: (2017-08-01)

OCT macular changes in type 1 ROP following Ranibizumab injections
by: Rawan Hosny, et al.
Published: (2025-04-01)

Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis
by: Shi-Dan Wang, et al.
Published: (2020-05-01)

Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience
by: Osman Parca, et al.
Published: (2024-03-01)

The results of diagnostic and treatment of patients with diabetic retinopathy and age-related macular degeneration at a diabetes type 2.
by: I. V. Vorobyova, et al.
Published: (2014-10-01)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
by: Thomas BJ, et al.
Published: (2016-08-01)

Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity
by: Fumio Takano, et al.
Published: (2024-07-01)

Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
by: Olapeju A. Sam-Oyerinde, et al.
Published: (2023-02-01)

Efficacy and safety of intravitreal anti-VEGF for myopic choroidal neovascularization
by: Jing-Yao Liu, et al.
Published: (2025-09-01)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
by: Carmen Antía Rodríguez-Fernández, et al.
Published: (2022-01-01)

Intravitreal ranibizumab for postlaser anterior segment ischemia in retinopathy of prematurity
by: Vasumathy Vedantham
Published: (2022-01-01)

Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use
by: Ramy M. Hanna, et al.
Published: (2020-10-01)

Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Oedema: Is It Safe?
by: Kuan Hao Yee, et al.
Published: (2017-10-01)

Efficacy of Intravitreal Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion and Resistant to Intravitreal Ranibizumab Injection
by: Ayşe Ergin, et al.
Published: (2022-12-01)

Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review
by: Yuen YS, et al.
Published: (2022-10-01)

Comparison of Ocular Biometry and Refraction in Children with Spontaneously Regressed ROP and those Treated with Laser or Anti-VEGF
by: Mehak Sethi, et al.
Published: (2025-09-01)

Comparison of ranibizumab and conbercept treatment in type 1 prethreshold retinopathy of prematurity in zone II
by: Xiu-Mei Yang, et al.
Published: (2024-08-01)

Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab
by: Ji Hye Jang
Published: (2024-07-01)

Comparison of Ranibizumab alone versus Ranibizumab with Targeted Retinal Laser for Branch Retinal Vein Occlusion with Macular Oedema.
by: Mohamed Abdelmoneem, et al.
Published: (2022-10-01)

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
by: Yue Zhao, et al.
Published: (2018-08-01)

Book Review: Anti-VEGF Use in Ophthalmology
by: Robin A. Vora
Published: (2017-09-01)

LncRNA TDRG1-Mediated Overexpression of VEGF Aggravated Retinal Microvascular Endothelial Cell Dysfunction in Diabetic Retinopathy
by: Qiaoyun Gong, et al.
Published: (2020-01-01)

Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema
by: Ma. Ludivina Robles-Osorio, et al.
Published: (2018-05-01)

EFFECT OF ANTI-VEGF THERAPY ON THE STRUCTURAL STATE OF THE RETINA IN DIABETIC MACULAR EDEMA
by: M. M. Bikbov, et al.
Published: (2016-11-01)

Macular oedema as manifestation of diabetic retinopathy
by: Mukharram M. Bikbov, et al.
Published: (2017-10-01)

Avaliação de fatores prognósticos a curto prazo com o uso de ranibizumabe em pacientes com edema macular diabético
by: Tereza Cristina Moreira Kanadani, et al.

Macular Thickness- An Early Predictor of Diabetic Macular Oedema
by: Chandrika Sareddy, et al.
Published: (2022-05-01)

Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity
by: Jing-Ke Cao, et al.
Published: (2023-04-01)

Diversity when interpreting evidence in network meta-analyses (NMAs) on similar topics: an example case of NMAs on diabetic macular oedema
by: Jing Wu, et al.
Published: (2023-10-01)